IMRX vs STT · $124.2M cap vs P/E 17, rev $7.84B
Immuneering Corp (IMRX) versus State Street Corp (STT) — a side-by-side from cached financials, not a winner call.
Immuneering Corp (IMRX) is a biotechnology company listed on US.
State Street Corp (STT) is a asset management company listed on US.
IMRX does not have a complete income-statement cache yet.
Latest reported STT revenue for 2026-06-30 was $7.84B. Net income was $1.85B. STT currently screens at market cap $45.02B and trailing P/E 16.5.
IMRX currently screens at market cap $124.2M. STT currently screens at market cap $45.02B and trailing P/E 16.5.
Not investment advice. Open the IMRX and STT stock pages for the full models.
Not investment advice.